Association between venous thromboembolism-associated genetic variants, coagulation factor levels, and thrombin generation potential.
genetic variant
procoagulant factor
the Netherlands epidemiology of obesity study
thrombin generation potential
venous thromboembolism
Journal
EJHaem
ISSN: 2688-6146
Titre abrégé: EJHaem
Pays: United States
ID NLM: 101761942
Informations de publication
Date de publication:
Feb 2024
Feb 2024
Historique:
received:
26
10
2023
revised:
23
01
2024
accepted:
26
01
2024
medline:
26
2
2024
pubmed:
26
2
2024
entrez:
26
2
2024
Statut:
epublish
Résumé
Recently three large meta-analyses of genome-wide association studies for venous thromboembolism (VTE) identified over 130 genetic variants. However, mechanisms by which newly identified and therefore underexplored VTE-associated genetic variants influence VTE remain unclear. To elucidate the mechanism, we investigated the association between 61 newly identified VTE-associated genetic variants and the levels of coagulation factor (F) VIII, FIX, FXI, and fibrinogen as well as thrombin generation parameters (lag time, peak, endogenous thrombin potential, time-to-peak, and velocity), which are well-known biological traits associated with VTE. This study was conducted on 5341 participants of the Netherlands Epidemiology of Obesity study. The associations between VTE-associated genetic variants and coagulation factor levels and thrombin generation parameters were examined using linear regression analyses, adjusted for age, sex, body mass index, oral contraceptive use, hormone replacement therapy, and menopausal status. Of 61 genetic variants, 33 were associated with one or more of the coagulation factor levels and thrombin generation parameters. Following multiple testing corrections, five genetic variants remained significant, of which
Identifiants
pubmed: 38406509
doi: 10.1002/jha2.863
pii: JHA2863
pmc: PMC10887265
doi:
Types de publication
Journal Article
Langues
eng
Pagination
47-54Informations de copyright
© 2024 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
Ruifang Li‐Gao is a part‐time consultant for Metabolon Inc. The other authors declare no conflict of interest.